Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study.
Muhammad Adnan Khattak(Edith Cowan University), John M. Kirkwood(UPMC Hillman Cancer Center), Luis de la Cruz‐Merino, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ruixuan Jiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter G. Mohr(Elbe Kliniken Stade-Buxtehude), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Spagnolo(Martin University), Jean‐Jacques Grob(Aix-Marseille Université), Jason J. Luke(University of Chicago), Caroline Robert(Inserm), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Matteo S. Carlino(The University of Sydney), Jacek Mackiewicz(Poznan University of Medical Sciences), Alexander M.M. Eggermont(University Medical Center Utrecht), Mizuho Fukunaga‐Kalabis(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k